Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors

Current Oncology Reports
Bastiaan G WortmanCarien L Creutzberg

Abstract

To provide an overview of common molecular risk factors in endometrial cancer (EC) with the possibility to improve adjuvant treatment selection. Recent studies have discovered and confirmed four different molecular subclasses in EC, with each having a distinct prognosis; POLE-ultramutated, microsatellite unstable, copy-number low, and copy-number high. Subsequent studies have shown that combining both molecular with clinicopathological risk factors can potentially improve adjuvant treatment selection for women with high-intermediate risk EC. For high risk and advanced stage EC, several molecular alterations are being explored for targeted therapy. Molecular alterations are frequently found in endometrial cancer and have currently not been implemented in the treatment guidelines for EC. Assessment of molecular alterations can distinguish patients that require less or more intensified adjuvant treatment. Trials investigating targeted therapies in EC are ongoing and have shown some promising results, however, more evidence is needed and results of randomized trials have to be awaited.

References

Apr 17, 2002·Human Pathology·Pilar MachinJaime Prat
Mar 22, 2003·Experimental Cell Research·Thomas HolbroNancy E Hynes
Aug 2, 2003·Gynecologic Oncology·Mahmoud A KhalifaIda Ackerman
Nov 5, 2003·The Journal of Pathology·A N ScholtenV T H B M Smit
Aug 7, 2004·Gynecologic Oncology·J M A PijnenborgP G Groothuis
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Israel ZighelboimDavid G Mutch
Mar 25, 2008·The American Journal of Surgical Pathology·Elizabeth ManionJamie Weydert
Sep 17, 2008·Oncogene·T L Yuan, L C Cantley
Jul 14, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Thomas HogbergGunnar Kristensen
Oct 15, 2010·The New England Journal of Medicine·Kimberly C WiegandDavid G Huntsman
Aug 1, 2012·The Lancet Oncology·Helga B SalvesenJone Trovik
Oct 20, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian M Slomovitz, Robert L Coleman
Mar 27, 2013·Human Molecular Genetics·David N ChurchIan P M Tomlinson
May 3, 2013·Nature·Cyriac KandothDouglas A Levine
Jun 20, 2013·Journal of the National Cancer Institute·Alain G ZeimetMina Fogel
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrea P Myers
Mar 1, 2014·Archives of Pathology & Laboratory Medicine·Natalia BuzaAlessandro D Santin
Mar 13, 2014·Cancer Biology & Therapy·Ren-Chin WuIe-Ming Shih
May 30, 2014·The Lancet Oncology·Rajmohan MuraliBritta Weigelt
Aug 16, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T BosseV T H B M Smit
Sep 13, 2014·Journal of the National Cancer Institute·Yuexin LiuWei Zhang
Nov 15, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Yaser R HusseinRobert A Soslow
Dec 17, 2014·Journal of the National Cancer Institute·David N ChurchTjalling Bosse
Jan 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian M SlomovitzRobert L Coleman
Feb 28, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Ellen StellooCarien L Creutzberg
Apr 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Inge C van GoolDavid N Church
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Jun 8, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tjalling BosseRemi A Nout
Jul 15, 2015·British Journal of Cancer·A TalhoukJ N McAlpine
Dec 5, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N ColomboUNKNOWN ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group
Jan 15, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Melissa K McConechyJessica N McAlpine
Mar 5, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Caroline C BillingsleyPaul J Goodfellow
Mar 24, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ellen StellooVincent T H B M Smit

❮ Previous
Next ❯

Citations

Dec 18, 2019·Histopathology·Lisa VermijTjalling Bosse
May 21, 2020·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·S MarnitzB Schömig-Markiefka
Aug 28, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Zachary D HorneSushil Beriwal
Aug 18, 2020·OncoTargets and Therapy·Yiran LiXiaoping Wan
Dec 31, 2020·International Journal of Molecular Sciences·Ivana FridrichovaKarol Kajo
Jun 12, 2021·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gitte OrtoftMargit Dueholm
Nov 12, 2021·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·S Marnitz

❮ Previous
Next ❯

Methods Mentioned

BETA
hysterectomy

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.